[
  {
    "table_index": 1,
    "headers": [],
    "rows": [
      [
        "End Note"
      ],
      [
        "Procite"
      ],
      [
        "Reference Manager"
      ]
    ],
    "row_count": 3,
    "column_count": 1
  },
  {
    "table_index": 2,
    "headers": [
      "Mechanistic classification",
      "Direct hepatotoxicity",
      "Idiosyncratic hepatotoxicity",
      "Indirect hepatotoxicity"
    ],
    "rows": [
      [
        "Incidence",
        "Common",
        "Rare",
        "Intermediate"
      ],
      [
        "Dose relatedness",
        "Yes",
        "No",
        "No"
      ],
      [
        "Predictable",
        "Yes",
        "No",
        "Partially"
      ],
      [
        "Reproduced in animal models",
        "Yes",
        "No",
        "Not usually"
      ],
      [
        "Latency",
        "Rapid (days)",
        "Variable (days to years)",
        "Delayed (months)"
      ],
      [
        "Phenotypes of injury",
        "Serum AST, ALT, or ALP elevations, hepatic necrosis, acute fatty liver, nodular regeneration",
        "Mixed or cholestatic hepatitis, bland cholestasis, chronic hepatitis",
        "Immune‐mediated hepatitis, fatty liver, chronic hepatitis"
      ],
      [
        "Examples",
        "Acetaminophen, niacin, intravenous methotrexate",
        "Amoxicillin‐clavulanate, cephalosporins, isoniazid, nitrofurantoin",
        "Immune checkpoint inhibitors, anti‐CD20 monoclonal Ab, protein kinase inhibitors"
      ],
      [
        "Touted mechanism of injury",
        "Intrinsic hepatotoxicity that is dose‐dependent",
        "Idiosyncratic host metabolic or immune reaction",
        "Indirect effect on liver or host immunity"
      ]
    ],
    "row_count": 8,
    "column_count": 4
  },
  {
    "table_index": 3,
    "headers": [
      "Country",
      "United States/DILIN, n = 899",
      "Spain, n = 843",
      "Iceland, n = 96",
      "Latin America, n = 311",
      "China, n = 25, 927",
      "India, n = 313/1288"
    ],
    "rows": [
      [
        "Study design",
        "Prospective registry30",
        "Prospective registry29",
        "Prospective, population‐based9",
        "Prospective registry18",
        "Retrospective case series22",
        "Prospective case series21,31"
      ],
      [
        "Publication year",
        "2015",
        "2021",
        "2013",
        "2019",
        "2019",
        "2010/2021"
      ],
      [
        "Age distribution, years",
        "49 ± 17",
        "54 (11–91)",
        "55¥(16–91)",
        "50 (11–91)",
        "43% (40–59 years)",
        "39 (12–84)/43 (1–86)"
      ],
      [
        "% Female",
        "59",
        "48",
        "56",
        "61",
        "49",
        "42/48.6"
      ],
      [
        "% Liver‐ and non‐liver‐related fatality",
        "Liver‐related: 3.0; non‐liver‐related: 3.2",
        "Liver‐related: 2.1; non‐liver‐related: 1.7",
        "Overall fatality: 1",
        "Overall fatality: 4.9",
        "Liver‐related: 0.28a; non‐liver‐related: 0.11a",
        "Overall fatality: 17.3/12.3"
      ],
      [
        "% Liver transplant",
        "3.7",
        "1.5",
        "0",
        "0",
        "0.01",
        "0"
      ],
      [
        "Top 3 implicated drug classes",
        "Antimicrobials, HDS, cardiovascular agents",
        "Anti‐infectives, CNS drugs, musculoskeletal drugs (including NSAID)",
        "Antibiotics, immuno‐suppressants, psychotropic drugs",
        "Antibiotics,bNSAIDs,bantitubercularb",
        "TCM or HDS, antitubercular, antineoplastic or immune modulators",
        "Antitubercular, HDS, antiepileptics"
      ],
      [
        "Top 10 implicated agents",
        "HDS, amoxicillin/clavulanate, isoniazid, nitrofurantoin, trimethoprim‐sulfamethoxazole, minocycline, cefazolin, azithromycin, ciprofloxacin, levofloxacin",
        "Amoxicillin/clavulanate, antitubercular, HDS, ibuprofen, anabolic androgenic steroids, flutamide, isoniazid, atorvastatin, diclofenac, ticlopidine",
        "Amoxicillin/clavulanate, diclofenac, infliximab, nitrofurantoin, isotretinoin, atorvastatin, doxycycline, azathioprine",
        "Amoxicillin/clavulanate, nitrofurantoin, diclofenac, RIP + INH + PIZ, nimesulide, ibuprofen, cyproterone, carbamazepine, methyldopa, atorvastatin",
        "Natural medicine, rifampicin, TCM, isoniazid, pyrazinamide, He Shou Wu, methimazole, propylthiouracil, atorvastatin, methotrexate",
        "Antitubercular, phenytoin, dapsone, olanzapine, carbamazepine, cotrimoxazole, NSAIDs, atorvastatin, leflunomide, ayurvedic"
      ]
    ],
    "row_count": 8,
    "column_count": 7
  },
  {
    "table_index": 4,
    "headers": [
      "Drug",
      "HLA group",
      "Genetic variants",
      "OR",
      "MAF in controlsa"
    ],
    "rows": [
      [
        "Multiple drugs58,61",
        "Non‐HLA",
        "PTPN22 (rs2476601)",
        "1.4",
        "0.08"
      ],
      [
        "rs72631567 (Chromosome 2)",
        "2.0",
        "0.03"
      ],
      [
        "Mixed/cholestatic",
        "HLA‐I",
        "A*33:01/rs114577328g",
        "5.0",
        "0.01"
      ],
      [
        "",
        "A*33:01/B*14:02/C*08:02.",
        "5.6",
        "0.009"
      ],
      [
        "Hepatocellular",
        "Non‐HLA",
        "rs28521457 (chromosome 4/LRBA)",
        "2.1",
        "0.04"
      ],
      [
        "Amoxicillin‐clavulanate62,63",
        "HLA‐I",
        "A*02:01 (rs2523822)",
        "2.3",
        "0.28/0.28b"
      ],
      [
        "",
        "A*30:02",
        "6.7 (HC)",
        "0.029"
      ],
      [
        "",
        "B*18:01",
        "2.9 (HC)",
        "0.096"
      ],
      [
        "HLA‐II",
        "DRB1*15:01/DQB1*06:02 (rs3135388)",
        "2.8",
        "0.14/0.05b"
      ],
      [
        "",
        "rs9274407",
        "3.1",
        "0.15/0.081b"
      ],
      [
        "",
        "rs9267992",
        "3.1",
        "0.14/0.063b"
      ],
      [
        "Non‐HLA",
        "PTPN22 (rs2476601)",
        "1.6",
        "0.08"
      ],
      [
        "Flucloxacillin64,65",
        "HLA‐I",
        "B*57:01",
        "36.6",
        "0.04"
      ],
      [
        "",
        "B*57:03",
        "79.2",
        "0.0003"
      ],
      [
        "Minocycline66",
        "HLA‐I",
        "HLA‐B*35:02",
        "29.6",
        "0.006"
      ],
      [
        "Trimethoprim‐sulfamethoxazole67",
        "HLA‐I",
        "A*34:02 (EUR)",
        "47.5",
        "0.001"
      ],
      [
        "",
        "B*14:01 (EUR)",
        "9.2",
        "0.009"
      ],
      [
        "",
        "B*27:02 (EUR)",
        "13.5",
        "0.002"
      ],
      [
        "",
        "HLA‐B*35:01 (AA)",
        "2.8d",
        "0.087"
      ],
      [
        "Isoniazid‐containing antitubercular treatments61,68",
        "Non‐HLA",
        "rs72631567 (Chromosome 2)",
        "5.8",
        "0.03"
      ],
      [
        "",
        "rs117491755 (ASTN2: EUR)",
        "4.4",
        "0.037"
      ],
      [
        "",
        "NAT2*6/*6, *6/*7, or *7/*7 (ultraslow) (EUR/IND)",
        "2.0/1.8",
        "0.10/0.19"
      ],
      [
        "HLA‐I",
        "C*12:02 (EUR)",
        "6.4",
        "0.006"
      ],
      [
        "",
        "B*52:01 (EUR)",
        "6.4",
        "0.007"
      ],
      [
        "",
        "B*52:01‐C*12:02 (EUR/IND)",
        "6.7/1.8",
        "0.01/0.07"
      ],
      [
        "HLA‐II",
        "DQA1*03:01(IND)",
        "2.6",
        "0.06"
      ],
      [
        "Terbinafine69",
        "HLA‐I",
        "A*33:01/rs114577328g",
        "40.5",
        "0.01–0.03"
      ],
      [
        "",
        "A*33:01/B*14:02/C*08:02",
        "49.2",
        "0.009"
      ],
      [
        "Valproate70",
        "Non‐HLA",
        "Mitochondrial DNA polymerase γ (POLG)",
        "23.6e",
        ""
      ],
      [
        "",
        "p.Q1236H",
        "",
        "≤ 0.086"
      ],
      [
        "",
        "p.E1143G",
        "",
        "≤ 0.04"
      ],
      [
        "Allopurinol71",
        "HLA‐I",
        "HLA‐A*34:02 (AA)",
        "8.0/4.5f",
        "0.033/0.057c"
      ],
      [
        "",
        "HLA‐B*53:01 (AA)",
        "4.1/2.5f",
        "0.120/0.184c"
      ],
      [
        "",
        "HLA‐B*58:01 (AA)",
        "5.6/13.3f",
        "0.046/0.020c"
      ],
      [
        "Green tea72",
        "HLA‐I",
        "B*35:01",
        "6.8",
        "0.06"
      ],
      [
        "",
        "C*04:01",
        "3.7",
        "0.12"
      ],
      [
        "Polygonum multiflorum73",
        "HLA‐I",
        "B*35:01",
        "30.4",
        "0.027"
      ]
    ],
    "row_count": 37,
    "column_count": 5
  },
  {
    "table_index": 5,
    "headers": [
      "Clinical phenotype",
      "Histological phenotype"
    ],
    "rows": [
      [
        "Hepatocellular",
        "Acute hepatitis",
        "Spotty necrosis, apoptosis, lobular inflammation, with or without portal inflammation and interface hepatitis",
        "Phenytoin, dapsone, para‐aminosalicylate, isoniazid, sulfonamides"
      ],
      [
        "Panlobular hepatitis",
        "Spotty or focal necrosis, acidophil bodies scattered throughout the lobule, hepatocytes with degenerative changes and lytic necrosis, lymphocytic infiltrates",
        "Immune checkpoint inhibitors (e.g., ipilimumab, nivolumab)"
      ],
      [
        "Zonal or nonzonal (confluent) necrosis",
        "Coagulative necrosis in zone 3 or panlobular involvement with either submassive or massive necrosis",
        "Acetaminophen, halothane, CCL4, cocaine, ferrous sulfate"
      ],
      [
        "Granulomatous hepatitis",
        "Noncaseating granulomas accompanied by significant inflammation; fibrin‐ring granulomas",
        "Sulfonamides, sulfonylurea, phenytoin, carbamazepine, quinidine, hydralazine, interferon‐α, etanercept, ipilimumab"
      ],
      [
        "Chronic hepatitis",
        "Similar to chronic viral hepatitis or autoimmune hepatitis with portal inflammation, interface hepatitis, fibrosis, or cirrhosis",
        "Atorvastatin, HDS, methotrexate, vinyl chloride"
      ],
      [
        "Drug‐induced AIH",
        "More prominent portal neutrophils than plasma cells along with cholestasis concurrently with the typical AIH histology of portal inflammation, interface hepatitis, rosette formation",
        "Nitrofurantoin, diclofenac, α‐methyldopa, hydralazine, minocycline, HMG‐CoA reductase inhibitors, TNF inhibitors"
      ],
      [
        "Cholestatic",
        "Acute cholestasis/bland cholestasis",
        "Bile accumulation in hepatocytes and/or bile canaliculi with little or no inflammation or hepatocyte injury",
        "Anabolic and oral contraceptives"
      ],
      [
        "Chronic cholestasis",
        "Bile accumulation, possibly bile duct loss/ductopenia, cholate stasis",
        "Amoxicillin‐clavulanate, flucloxacillin, enalapril, antifungal terbinafine"
      ],
      [
        "Acute cholestatic hepatitisMixed hepatocellular/cholestatic",
        "Bile accumulation in hepatocytes and/or bile canaliculi with more prominent inflammation and hepatocyte injury",
        "Antibiotics (erythromycin, amoxicillin‐clavulanate), ACE inhibitors, phenothiazine neuroleptics"
      ],
      [
        "Sclerosing cholangitis",
        "Bile duct injury with intraepithelial lymphocytic infiltration and periductal fibrosis",
        "Nivolumab"
      ],
      [
        "Fatty liver (drug‐induced steatosis, drug‐induced steatohepatitis)",
        "Pure microvesicular",
        "Numerous small droplets, foamy cytoplasm, hepatocyte nuclei retained in the center",
        "Acetylsalicylic acid (Reye syndrome), valproic acid, glucocorticoids, aspirin, NSAIDS, tetracycline, NRTI, cocaine"
      ],
      [
        "Macrovesicular",
        "Medium‐sized or large‐sized fat droplets with hepatocyte nuclei displaced to the periphery",
        "Glucocorticoids, methotrexate, NSAIDs, metoprolol, chlorinated hydrocarbons (e.g., CCL4and chloroform), 5‐fluorouracil, cisplatin, irinotecan, tamoxifen"
      ],
      [
        "Mixed macrovesicular and microvesicular",
        "Combination of small and large droplet",
        "Amiodarone, valproic acid, methotrexate"
      ],
      [
        "Steatohepatitis",
        "Presence of ballooning, inflammation, Mallory‐Denk hyalines, and fibrosis, in a background of steatosis",
        "Amiodarone, methotrexate, 5‐floururacil, cisplatin, irinotecan, tamoxifen"
      ],
      [
        "Vascular",
        "Sinusoidal obstruction syndrome",
        "Sinusoidal congestion with hepatocyte necrosis, red blood cells trapped in Disse spaces, perisinusoidal fibrosis, fibrous obliteration of terminal hepatic venules; sloughing of endothelial cells",
        "Busulfan, cyclophosphamide, plants containing pyrrolizidine alkaloids"
      ],
      [
        "",
        "NRH and OPV",
        "Small (1 mm) hyperplastic nodules bordered by atrophic hepatocyte plates (NRH); may require a reticulin stain. OPV will show either dilated and herniated portal veins or sclerotic lumina",
        "Arsenic, copper sulfate, azathioprine, methotrexate, 6‐mercaptopurine, oxaliplatin, didanosine, stavudine"
      ],
      [
        "",
        "Peliosis hepatis",
        "Blood‐filled sinusoidal spaces",
        "Androgens and oral contraceptives"
      ],
      [
        "Chronic DILI",
        "Fibrosis/cirrhosis",
        "Progression of fibrosis similar to chronic viral hepatitis",
        "Methotrexate, valproic acid, HDS, oral contraceptives, isoniazid, trimethoprim‐sulfamethoxazole, nitrofurantoin, methotrexate, diclofenac, fenofibrate, amoxicillin‐clavulanate"
      ],
      [
        "Miscellaneous",
        "Ground‐glass cytoplasm (induction hepatocytes), Lafora body‐like inclusions",
        "Homogeneous light pink cytoplasmic inclusions with displacement of the nuclei",
        "Barbiturates, phenytoin, polypharmacy; immunosuppressive agents, antibiotics"
      ],
      [
        "Phospholipidosis",
        "Enlarged, granular, or foamy cytoplasm; may require electron microscopy to check for lamellar bodies",
        "Antibiotics, antipsychotic, antidepressants, antianginal, antimalarial, antiarrhythmic, cholesterol‐lowering agents; amiodarone"
      ],
      [
        "Pigment deposition",
        "Ceroid‐containing macrophages; lipofuscin",
        "6‐mercaptopurine, phenothiazine, aminopyrine, phenacetin,"
      ],
      [
        "Neoplastic",
        "Hepatocellular adenoma",
        "All subtypes possible; most common are inflammatory and HNF‐1‐alpha mutated",
        "Oral contraceptives, anabolic and male hormone steroids, danazol"
      ]
    ],
    "row_count": 22,
    "column_count": 2
  },
  {
    "table_index": 6,
    "headers": [
      "Data field",
      "Updated RUCAM108score",
      "CDS109score",
      "RECAM113score"
    ],
    "rows": [
      [
        "1. Chronology (latency)",
        "",
        "",
        ""
      ],
      [
        "1a. Drug start to liver injury onseta",
        "+1 to +2",
        "+1 to +3",
        "−6 to +4"
      ],
      [
        "1b. Drug discontinuation to liver injury onseta",
        "+1",
        "−3 to +3",
        "−6 to 0"
      ],
      [
        "2. Dechallengeb",
        "−2 to +3 hepatocellular; 0 to +2 cholestatic/mixed",
        "0 to +3",
        "−6 to +4"
      ],
      [
        "3. Competing causes of liver injury",
        "−3 to +2",
        "−3 to +3",
        "−6 to 0"
      ],
      [
        "4. Rechallenge",
        "0 to +3",
        "+3",
        "0 or + 6"
      ],
      [
        "5. Track record of drug/HDS hepatotoxicity",
        "0 to +2",
        "−3 to +2",
        "0 to +3"
      ],
      [
        "Risk factors",
        "0 to +1",
        "N/A",
        "N/Ac"
      ],
      [
        "6. Concomitant medication",
        "−3 to 0",
        "N/A",
        "N/Ad"
      ],
      [
        "7. Extrahepatic manifestations",
        "–",
        "0 to +3",
        "–"
      ],
      [
        "Range of scores",
        "−9 to +14",
        "−6 to 17",
        "−6 to +20"
      ],
      [
        "DILI likelihood categories",
        "",
        "",
        ""
      ],
      [
        "Definite",
        "≥ 9",
        "> 17",
        "Highly likely/high probable ≥ 8"
      ],
      [
        "Probable",
        "6–8",
        "14–17",
        "4–7"
      ],
      [
        "Possible",
        "3–5",
        "10–13",
        "−3 to +3"
      ],
      [
        "Unlikely",
        "1–2",
        "6–9",
        "Unlikely/excluded, < −4"
      ],
      [
        "Excluded",
        "≤ 0",
        "≤ 6"
      ]
    ],
    "row_count": 17,
    "column_count": 4
  },
  {
    "table_index": 7,
    "headers": [
      "Causality score",
      "Likelihood, %",
      "Description"
    ],
    "rows": [
      [
        "1. Definite beyond any reasonable doubt",
        "> 95",
        ""
      ],
      [
        "2 Highly likely",
        "75–95",
        "Clear and convincing data, but not definite"
      ],
      [
        "3. Probable",
        "50–74",
        "Most data support causal relationship"
      ],
      [
        "4. Possible",
        "25–49",
        "Most data suggest no causal relationship, but possibility remains"
      ],
      [
        "5. Unlikely",
        "< 25",
        "Causal relationship very unlikely, with alternative etiology more likely"
      ],
      [
        "6. Insufficient data",
        "Determinable",
        "Missing key data"
      ]
    ],
    "row_count": 6,
    "column_count": 3
  },
  {
    "table_index": 8,
    "headers": [
      "Ingredient",
      "Chemical structure",
      "Common uses",
      "Hepatotoxicity phenotype",
      "Expected outcome"
    ],
    "rows": [
      [
        "Ashwagandha,135Withania somnifera",
        "Steroidal lactone",
        "Neuroprotection, anti‐inflammatory",
        "Cholestatic or mixed",
        "Recovery expected"
      ],
      [
        "Green tea extract72,132",
        "Catechin‐polyphenol",
        "Weight loss",
        "Hepatocellular",
        "Most recover; liver failure, transplant, death reported"
      ],
      [
        "Garcinia cambogia136",
        "(−)‐hydroxycitric acid",
        "Weight loss",
        "Hepatocellular",
        ""
      ],
      [
        "Polygonum multiflorum73,137",
        "Stilbenes and anthraquinones",
        "Anti‐aging, intestinal function",
        "Hepatocellular or mixed",
        "Most recover; fatalities reported"
      ],
      [
        "Chinese skullcap,Scutellaria baicalensis;Scutellaria lateriflora",
        "Flavonoid",
        "Anxiety, insomnia, neurological disorders",
        "Hepatocellular",
        "Recovery typical"
      ],
      [
        "Kratom,138Mitragyna speciosa",
        "Tetracyclic indole and pentacyclic oxindole alkaloids",
        "Anxiety, opiate effect, or withdrawal",
        "Mixed",
        "Recovery typical"
      ],
      [
        "Anabolic steroids139",
        "Steroid backbone",
        "Bodybuilding, performance enhancement",
        "Cholestasis",
        "Prolonged jaundice, full recovery"
      ],
      [
        "Turmeric/curcumin140–142",
        "Polyphenol",
        "Anti‐inflammatory, weight loss, anticancer, cardiovascular disease",
        "Hepatocellular",
        "Recovery expected; one case of AIH reported"
      ]
    ],
    "row_count": 8,
    "column_count": 5
  },
  {
    "table_index": 9,
    "headers": [
      "Model/parameter",
      "Model components",
      "Proposed thresholds for liver transplant/death",
      "Comments"
    ],
    "rows": [
      [
        "MELD score143",
        "Bilirubin, INR, and creatinine",
        "AUROC = 0.83",
        "Developed for cirrhosis patients"
      ],
      [
        "Hy's law145",
        "ALT > 3× ULN and bilirubin > 2.5 mg/dl",
        "PPV = 8%–20%",
        "ALP should be < 2× ULN; not applicable to mixed/cholestatic cases"
      ],
      [
        "Modified Hy's law144",
        "R‐value > 5 and bilirubin > 2.5 mg/dl",
        "PPV = 12%; AUROC = 0.73",
        ""
      ],
      [
        "Charlson Comorbidity Index and labs146a",
        "MELD score, albumin, Charlson > 2",
        "AUROC = 0.89",
        "Discovery and validation cohort used for 6‐month mortality"
      ]
    ],
    "row_count": 4,
    "column_count": 4
  },
  {
    "table_index": 10,
    "headers": [
      "Intervention",
      "Target population",
      "Dosing",
      "Comments"
    ],
    "rows": [
      [
        "General intervention",
        "",
        "",
        ""
      ],
      [
        "APAP analgesics",
        "Mild to moderate pain",
        "2 g maximum per day in divided doses",
        "Consider short acting opiates if moderate to severe pain"
      ],
      [
        "Antiemetics",
        "Moderate nausea/vomiting",
        "Per package insert",
        ""
      ],
      [
        "Ursodeoxycholic acid",
        "Severe pruritus",
        "10–15 mg/kg in divided doses",
        "Prospective efficacy data lacking; likely safe"
      ],
      [
        "Hospitalization",
        "Dehydrated, coagulopathic, encephalopathic patients",
        "NA",
        "Transfer to transplant center if ALF"
      ],
      [
        "N‐acetylcysteine",
        "Hospitalized with ALF",
        "See  for dosing; 72‐h duration in studies",
        "Requires cardiac monitoring (i.v.); greatest benefit in early‐stage ALF"
      ],
      [
        "Corticosteroids",
        "Severe hypersensitivity reactions; DRESS; checkpoint inhibitor with ALT > 5× ULN; histology showing AIH‐like features",
        "1 mg/kg per day of methylprednisolone equivalents for ICI cases; 40–60 mg of prednisone for others",
        "Optimal dose and duration not established but frequently can be tapered in 1–3 months"
      ],
      [
        "Drug‐specific interventions",
        "",
        "",
        ""
      ],
      [
        "l‐carnitine",
        "Valproate with hyperammonemia (hospitalized children)",
        "100 mg/kg load followed by 50 mg/kg every 8 h",
        "Short‐term use"
      ],
      [
        "Cholestyramine",
        "Leflunomide cases with persistent cholestasis",
        "1 packet every 6–8 h for 14 days",
        "Taper once cholestasis/pruritus resolves; give separately from other medications"
      ],
      [
        "Penicillin (i.v.)/silymarin and dialysis",
        "Amanita mushroom toxicity",
        "Hospitalized patients or ALF",
        "Short‐term use to remove enterohepatic toxin"
      ],
      [
        "Defibrotide (i.v.)",
        "Hematopoietic cell transplant recipients with severe sinusoidal obstruction syndrome",
        "6.25 mg/kg every 6 h for > 21 days up to a maximum of 60 days",
        "Shown to improve survival in children and adults compared with historical controls"
      ]
    ],
    "row_count": 12,
    "column_count": 4
  },
  {
    "table_index": 11,
    "headers": [
      "Recommendation",
      "Intentional overdose",
      "Unintentional overdose"
    ],
    "rows": [
      [
        "Diagnostic approach",
        "",
        ""
      ],
      [
        "Time of ingestion",
        "Single time point",
        "Several days of repeated use"
      ],
      [
        "Dose",
        "Supratherapeutic (typically > 4 g over 24 h)",
        "Repeated therapeutic (up to 4 g per day) or supratherapeutic dosing"
      ],
      [
        "Presence of coingestants",
        "Diphenhydramine and other sedatives can lead to central nervous system depression",
        "Opioids often used in combination"
      ],
      [
        "Liver injury parameters",
        "From time of ingestion: 24–72 h: rapid rise in ALT to > 1000 IU/L associated with variable rise in INR; total bilirubin is typically < 10 mg/dl. 72–96 h: Biochemical elevations peak, and can progress to acute liver failure or rapid and full recovery",
        "Presentation is often delayed, but still see rapid rise in ALT to > 1000 IU/L, associated with rise in INR. Comorbid conditions, such as alcohol use, can affect total bilirubin levels. Eventually, liver injury can progress to acute liver failure or recovery"
      ],
      [
        "Serum APAP level",
        "Use modified Rumack‐Matthew nomogram to estimate risk of hepatotoxicity",
        "Often undetectable at initial presentation. APAP‐protein adducts useful but assay not commercially available"
      ],
      [
        "Excluding other causes of acute liver injury",
        "Review clinical history to exclude risk factors for hepatic ischemia and perform tests for acute viral hepatitis"
      ],
      [
        "Management",
        "",
        ""
      ],
      [
        "GI decontamination",
        "Activated charcoal (1 g/kg, max dose 50 g) if within 4 h of ingestion. Gastric lavage also used in some cases175",
        "Usually not helpful nor recommended"
      ],
      [
        "N‐acetylcysteine",
        "Oral dosing: 140 mg/kg load followed by 70 mg/kg every 4 h; antiemetics as needed. Intravenous dosing176: preferred if intolerant of oral intake/ileus or pregnant; telemetry monitoring recommended 150 mg/kg load over 15–60 min, followed by 50 mg/kg (12.5 mg/kg/h) over the next 4 h then 100 mg/kg (6.25 mg/kg/h) over 16 h thereafter (total 300 mg/kg over 24 h). For those with evidence of liver injury, treatment is extended at 6.25 mg/kg/h until ALT is decreasing and INR is < 2"
      ],
      [
        "Evidence of acute liver failure (coagulopathy and encephalopathy)",
        "Close monitoring in intensive care unit and consider prompt referral to a liver transplant center"
      ]
    ],
    "row_count": 11,
    "column_count": 3
  }
]